Difficulty: Medium
Average Score: 62%
Practice
What is one reason why patients with CHD are more likely to have rejection post-transplant than those with cardiomyopathy?
Correct answer
A
Rationale
The correct answer is A) Sensitized recipients with panel reactive antibody (PRA). Patients with congenital heart disease (CHD) are more likely to experience rejection post-transplant compared to those with cardiomyopathy due to their increased likelihood of being sensitized recipients. CHD patients often require multiple surgeries and blood transfusions during their lifetime, leading to the development of antibodies against human leukocyte antigens (HLA) in the donated heart. These panel reactive antibodies (PRA) can recognize and attack the transplanted organ, triggering rejection.
Option B) Absence of systemic disease is incorrect because the presence or absence of systemic disease is not a significant factor in the likelihood of rejection post-transplant in CHD patients.
Option C) History of good compliance is incorrect as well because while compliance with post-transplant medications and follow-up care is important in preventing rejection, it is not the primary reason why CHD patients are more prone to rejection compared to those with cardiomyopathy.
Understanding the factors that contribute to rejection post-transplant in pediatric patients with CHD is crucial for healthcare providers involved in their care. It underscores the importance of pre-transplant screening for panel reactive antibodies and the need for close monitoring and immunosuppressive therapy post-transplant to minimize the risk of rejection. This knowledge helps optimize patient outcomes and improve the success rates of heart transplants in pediatric populations with CHD.
Option B) Absence of systemic disease is incorrect because the presence or absence of systemic disease is not a significant factor in the likelihood of rejection post-transplant in CHD patients.
Option C) History of good compliance is incorrect as well because while compliance with post-transplant medications and follow-up care is important in preventing rejection, it is not the primary reason why CHD patients are more prone to rejection compared to those with cardiomyopathy.
Understanding the factors that contribute to rejection post-transplant in pediatric patients with CHD is crucial for healthcare providers involved in their care. It underscores the importance of pre-transplant screening for panel reactive antibodies and the need for close monitoring and immunosuppressive therapy post-transplant to minimize the risk of rejection. This knowledge helps optimize patient outcomes and improve the success rates of heart transplants in pediatric populations with CHD.